| scholarly article | Q13442814 |
| P50 | author | Malalage N Peiris | Q84002441 |
| P2093 | author name string | Daniel J Donoghue | |
| Fangda Li | |||
| P2860 | cites work | Common fragile sites associated with the breakpoints of chromosomal aberrations in hematologic neoplasms | Q77908383 |
| A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia | Q81338085 | ||
| Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review | Q90826216 | ||
| Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia | Q92113698 | ||
| Distinct signaling programs associated with progression of FGFR1 driven leukemia in a mouse model of stem cell leukemia lymphoma syndrome | Q93139352 | ||
| The BCR gene encodes a novel serine/threonine kinase activity within a single exon | Q24311992 | ||
| The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein | Q24553320 | ||
| GeneCards Version 3: the human gene integrator | Q24610308 | ||
| The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain | Q24683045 | ||
| Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia | Q26785828 | ||
| Structure of the Bcr-Abl oncoprotein oligomerization domain | Q27637200 | ||
| Solution structure and backbone dynamics of the AF-6 PDZ domain/Bcr peptide complex | Q27644666 | ||
| Activation of tyrosine kinases by mutation of the gatekeeper threonine | Q27652166 | ||
| Structure and chemical inhibition of the RET tyrosine kinase domain | Q28259608 | ||
| Duplication of small segments within the major breakpoint cluster region in chronic myelogenous leukemia | Q28267208 | ||
| BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner | Q28275554 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| GEFs and GAPs: critical elements in the control of small G proteins | Q28304540 | ||
| Src homology 2 domain containing protein 5 (SH2D5) binds the breakpoint cluster region protein, BCR, and regulates levels of Rac1-GTP | Q28507704 | ||
| Abnormal function of astroglia lackingAbrandBcrRacGAPs | Q28511987 | ||
| Abr and Bcr, two homologous Rac GTPase-activating proteins, control multiple cellular functions of murine macrophages | Q28594416 | ||
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia | Q29614280 | ||
| A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy | Q30008755 | ||
| BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein | Q30194769 | ||
| Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. | Q33831776 | ||
| Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics | Q33899740 | ||
| Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase | Q34182738 | ||
| Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. | Q34206916 | ||
| The BCR gene and philadelphia chromosome-positive leukemogenesis. | Q34209514 | ||
| Mapping of four distinct BCR-related loci to chromosome region 22q11: order of BCR loci relative to chronic myelogenous leukemia and acute lymphoblastic leukemia breakpoints | Q34353700 | ||
| BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia | Q34524461 | ||
| Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia | Q34771074 | ||
| Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals | Q35056472 | ||
| Causes of oncogenic chromosomal translocation | Q35570942 | ||
| Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide | Q35598699 | ||
| Molecular insights into regulation of JAK2 in myeloproliferative neoplasms | Q35661987 | ||
| The BCR-ABL story: bench to bedside and back | Q35698382 | ||
| The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. | Q35740647 | ||
| The landscape and therapeutic relevance of cancer-associated transcript fusions. | Q35744353 | ||
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
| The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. | Q44002734 | ||
| Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia | Q44807955 | ||
| Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes | Q45062950 | ||
| How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated? | Q46092927 | ||
| TumorFusions: an integrative resource for cancer-associated transcript fusions. | Q47207132 | ||
| The BCR gene recombines preferentially with Alu elements in complex BCR- ABL translocations of chronic myeloid leukaemia | Q48038016 | ||
| Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. | Q48109911 | ||
| The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase. | Q49723864 | ||
| Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation | Q50721189 | ||
| Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial | Q52641875 | ||
| FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome. | Q52714441 | ||
| Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy | Q54274051 | ||
| Incidence of bcr‑abl fusion transcripts in healthy individuals | Q54376567 | ||
| RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation | Q54516478 | ||
| BCR-PDGFRA fusion in a T lymphoblastic leukemia/lymphoma. | Q55055637 | ||
| Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter S | Q56959848 | ||
| Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response | Q58449580 | ||
| The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3 | Q58483483 | ||
| Loss of the BCR-FGFR1 GEF domain suppresses RHOA activation and enhances B-lymphomagenesis in mice | Q58562138 | ||
| ABR, an active BCR-related gene | Q35953624 | ||
| Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia | Q36047171 | ||
| IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease | Q36161397 | ||
| A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia | Q36185370 | ||
| Atlas of Genetics and Cytogenetics in Oncology and Haematology in 2013 | Q36491382 | ||
| Structure and Physiology of the RET Receptor Tyrosine Kinase | Q36555201 | ||
| Identification and characterization of RET fusions in advanced colorectal cancer | Q36557174 | ||
| The impact of translocations and gene fusions on cancer causation | Q36760027 | ||
| Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia | Q37035173 | ||
| Chromosomal translocations in cancer | Q37249033 | ||
| Regulation of synaptic Rac1 activity, long-term potentiation maintenance, and learning and memory by BCR and ABR Rac GTPase-activating proteins. | Q37361588 | ||
| The Rac-GAP Bcr is a novel regulator of the Par complex that controls cell polarity. | Q37387817 | ||
| The cancer stem cell: premises, promises and challenges | Q37851011 | ||
| A comprehensive transcriptional portrait of human cancer cell lines | Q37854720 | ||
| Central role of RET in thyroid cancer | Q38167995 | ||
| Engineering CAR-T cells: Design concepts | Q38290031 | ||
| A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. | Q38307018 | ||
| Epidemiology of chronic myeloid leukaemia: an update | Q38392709 | ||
| Long Non-Coding RNAs: New Players in Hematopoiesis and Leukemia | Q38450930 | ||
| Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm | Q38478174 | ||
| Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations | Q38499948 | ||
| Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase | Q38760092 | ||
| Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population | Q38850383 | ||
| Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders. | Q39042149 | ||
| BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. | Q39122060 | ||
| PDGFs and their receptors | Q39166181 | ||
| Long Noncoding RNA and Cancer: A New Paradigm | Q39431288 | ||
| Fusion gene microarray reveals cancer type-specificity among fusion genes | Q39595452 | ||
| Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors | Q39861042 | ||
| Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells | Q40228137 | ||
| A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation | Q40350288 | ||
| A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins | Q40657033 | ||
| Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors | Q40678515 | ||
| Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor | Q40710486 | ||
| An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias | Q40872589 | ||
| Tyrosine phosphorylation enhances the SH2 domain-binding activity of Bcr and inhibits Bcr interaction with 14-3-3 proteins | Q40941986 | ||
| Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. | Q41120068 | ||
| Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity | Q41356541 | ||
| Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family | Q41436352 | ||
| Fall of the mutants: T cells targeting BCR-ABL. | Q42324198 | ||
| Regional localization and developmental expression of the BCR gene in rodent brain | Q42954773 | ||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chromosomal translocation | Q916504 |
| leukemia | Q29496 | ||
| RTK | Q54951415 | ||
| P304 | page(s) | 2738-2754 | |
| P577 | publication date | 2019-04-12 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | BCR: a promiscuous fusion partner in hematopoietic disorders | |
| P478 | volume | 10 |
| Q98776114 | Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors | cites work | P2860 |
Search more.